Latest News
European private equity firm, Cinven, has completed the sale of Phadia Group, the leading in-vitro allergy diagnostics company based in Uppsala (Sweden), to Thermo Fisher Scientific Inc.
Cinven announced the agreement to sell Phadia Group in May 2011 for an enterprise value of EUR2.47 billion. Cinven’s Healthcare team led the acquisition of Phadia in early 2007 for an enterprise value of EUR1.285 billion. T
he sale of Phadia will return a 3.4x multiple to its fund, representing a capital gain of around EUR1bn. This marks the successful execution of the investment thesis pursued by Cinven and management, which resulted in
The volatility of the stock and bond markets are causing Institutional, Pension, Foundation and Endowment investors to rethink their portfolio diversification strategies and seek an alternative path to minimize market disruptions that provide more consistent returns with lower volatility over time. With the unusually strong showing of the Initial Public Offering (IPO) markets just a few months ago followed by a virtual market collapse, the longer term, lower volatility of the venture capital and private equity asset classes have renewed investor interest, says Igor Sill, founder of Geneva Venture Partners…
The tremendous success of Venture Capital funded Linkedin’s public market debut
Olswang has advised the shareholders of Pathway Care Group Limited, including funds managed by ISIS Equity Partners (ISIS), on the sale to Fostering Solutions Limited.
After a six year investment in the organisation, which saw significant expansion across the UK and involved increasing the foster carer base from 210 to 570, the shareholders have sold the UK’s fourth largest independent fostering agency.
Adam Holloway of ISIS says: “This has been a very intensive and rewarding investment. Our approach to supporting growth and reinvesting cashflow has helped to build a quality business that has consistently delivered for all its stakeholders, including
George Little Management (GLM) and Providence Equity Partners have signed a definitive merger agreement under which affiliates of Providence will acquire GLM from Daily Mail and General Trust plc (LSE: DMGT.L) for approximately USD173 million in cash.
GLM creates face-to-face and online buying, selling and networking platforms for designers, product developers, manufacturers, reps, retailers and operators through tradeshow and event production, online community development and association management. GLM currently produces 15 tradeshows, serving industries as diverse as giftware, home furnishings, social stationery, home textiles, tabletop, gourmet housewares, contemporary furniture, personal care, art & design, antique jewellry, beach, board sports, fashion
Spinifex Pharmaceuticals, an Australian pain drug development company, has secured a further AUD6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.
This expanded Series B funding builds on a previously announced AUD12 million investment from the same syndicate and will be used in part to expand the Phase 2 clinical trial program for EMA401 to a further two indications, specifically; the treatment of pain and hypersensitivity in peripheral nerve injury patients; and the treatment of pain
KalVista Pharmaceuticals (KalVista), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
The company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and a major unmet medical need. KalVista’s advanced pre-clinical product pipeline is targeting both intravitreal injection and oral administration routes. KalVista acquired these inhibitors plus all relevant intellectual property from Vantia Therapeutics.
KalVista’s scientific founders
Ogier Fiduciary Services Cayman Limited (OFSCL) has announced a new management structure designed to allow its leadership team to focus and develop capabilities for specific lines of business and build even deeper partnerships with clients.
“The growth and diversification of the fiduciary services business and Ogier Cayman overall has required us to look at our operating philosophy and structure in terms of current and prospective client needs,” says Colin MacKay, Group Director, Ogier Fiduciary Services. “The changes we’re announcing today reflect client demand for specialised capabilities across our lines of business and put us in an excellent position to capitalise
Chinese buyers have continued to show their strength in 2011 despite ongoing global economic uncertainty, according to a new report from Robert W Baird & Co, a global investment bank with extensive experience in middle market, cross-border M&A and offices in Shanghai and Hong Kong.
Baird’s latest twice-yearly China M&A Market report shows that outbound M&A rose strongly in the first half of this year, with the number of majority-interest deals up more than 40% on the same period in 2010. In value terms, the rise was 50%. The story for inbound M&A was in stark contrast, as the deal
Global private equity firm Vector Capital has completed its USD283, acquisition of Gerber Scientific, Inc, an international supplier of sophisticated automated manufacturing systems for the sign making, specialty graphics, packaging, apparel and industrial industries.
CITIC Capital Partners, a China based private equity firm, will take a minority stake in Gerber Scientific alongside Vector.
Gerber Scientific’s stockholders approved the take-private transaction at a special meeting of the stockholders on 18 August, 2011. Under the terms of the merger agreement, Gerber Scientific stockholders will receive USD11.00 per share in cash, plus a non-transferable contractual right to receive additional contingent cash consideration payments
Fund administrator HedgeServ has expanded its international platform with the opening of an office in London on 22 August.
The office, located at 21 Upper Brook Street, W1, will focus on business development with hedge funds, funds of hedge funds, private equity funds, and institutional investment managers.
"Our entry into London reflects our commitment to answering the global demand for HedgeServ’s innovative, high-quality fund administration services," says Justin Nadler, president of HedgeServ. "We are well-positioned to deliver local expertise to clients through our growing London presence and our established Dublin office, with 250 experienced fund accounting, middle-office operations, and investor
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
